Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Safety and Efficacy of Natalizumab in Children With Multiple Sclerosis
Neurol 75:912-917, Ghezzi,A.,et al, 2010
Cyclophosphamide Therapy in Pediatric Multiple Sclerosis
Neurol 72:2076-2082,2064, Makhani,N.,et al, 2009
Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008
Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006
Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis
Brain 126:433-437, Filippi,M.,et al, 2003
Early Onset Multiple Sclerosis
Neurol 59:1006-1010, Boiko,A.,et al, 2002
Multiple Sclerosis
NEJM 343:938-952, Noseworthy,J.H. et al, 2000
Improvement in Multiple Sclerosis during Prolonged Induced Hypothermia
Neurol 27:302, Symington,G.R.,et al, 1977